These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 34021797)

  • 1. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
    Ozsurekci Y; Oygar PD; Gürlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gülhan B; Topaloglu R; Bayrakci B; Cengiz AB
    Pediatr Nephrol; 2021 Nov; 36(11):3771-3776. PubMed ID: 34021797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
    Shohan M; Nashibi R; Mahmoudian-Sani MR; Abolnezhadian F; Ghafourian M; Alavi SM; Sharhani A; Khodadadi A
    Eur J Pharmacol; 2022 Jan; 914():174615. PubMed ID: 34863994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
    Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury in children with COVID-19: a retrospective study.
    Kari JA; Shalaby MA; Albanna AS; Alahmadi TS; Alherbish A; Alhasan KA
    BMC Nephrol; 2021 May; 22(1):202. PubMed ID: 34059010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
    Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
    Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical analysis of acute kidney injury in pediatric COVID-19 patients in the intensive care unit.
    Raina R; Chakraborty R; Mawby I; Agarwal N; Sethi S; Forbes M
    Pediatr Nephrol; 2021 Sep; 36(9):2627-2638. PubMed ID: 33928439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned.
    Sürmelioğlu N; Demirtürk E; Ateş Ayhan N; Özel Yeşilyurt A; Bayrakçi S; Kaynak MS; Özyılmaz E; Allegaert K
    Int J Clin Pharmacol Ther; 2024 Aug; 62(8):345-352. PubMed ID: 38920081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Kidney Injury in Pediatric Inflammatory Multisystem Syndrome Temporally Associated With Severe Acute Respiratory Syndrome Coronavirus-2 Pandemic: Experience From PICUs Across United Kingdom.
    Deep A; Upadhyay G; du Pré P; Lillie J; Pan D; Mudalige N; Kanthimathinathan HK; Johnson M; Riphagen S; Dwarakanathan B; Raffaj D; Sundararajan S; Davies P; Mohammad Z; Shetty N; Playfor S; Jardine M; Ross O; Levin R; Waters G; Sinha R; Scholefield BR; Boot E; Koul A; Freire-Gomez X; Ramnarayan P
    Crit Care Med; 2020 Dec; 48(12):1809-1818. PubMed ID: 33044282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
    Ramzy S; Abdelazim AH; Osman AO; Hasan MA
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Triggering Severe Acute Respiratory Distress Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in a 3-Year-Old Child With Down Syndrome.
    Kim-Hellmuth S; Hermann M; Eilenberger J; Ley-Zaporozhan J; Fischer M; Hauck F; Klein C; Haas N; Kappler M; Huebner J; Jakob A; von Both U
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):543-546. PubMed ID: 33188394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19.
    Irie K; Nakagawa A; Fujita H; Tamura R; Eto M; Ikesue H; Muroi N; Tomii K; Hashida T
    Clin Transl Sci; 2020 Sep; 13(5):880-885. PubMed ID: 32475019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease 2019.
    Koshi E; Saito S; Okazaki M; Toyama Y; Ishimoto T; Kosugi T; Hiraiwa H; Jingushi N; Yamamoto T; Ozaki M; Goto Y; Numaguchi A; Miyagawa Y; Kato I; Tetsuka N; Yagi T; Maruyama S
    CEN Case Rep; 2021 Feb; 10(1):126-131. PubMed ID: 32940880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.